Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang Pharmaceutical is a KOSPI-listed (185750) drugmaker based in Seoul. Its immunology candidate CKD-506 has completed a Phase 2 study in rheumatoid arthritis in Europe.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSPI:185750 |
| Lead asset / stage | CKD-506 Phase 2 — Europe (rheumatoid arthritis; completed) |
| Latest event | Chong Kun Dang announced that its Dermagram PDRN cream was being highlighted as a recommended K-pharmacy shopping product. |